A 2024 study found that GLP-1 peptides directly inhibit the TRPV1 pain receptor, which is sometimes called the chilli pepper receptor because its the one that responds to capsaicin [6]
The drug is being developed by Eli Lilly and Company, the same pharmaceutical manufacturer behind tirzepatide (Mounjaro), which has received MHRA approval in the UK for type 2 diabetes and, more recently, for weight management
Patients with proliferative retinopathy or maculopathy resulting in active treatment were excluded from the PIONEER 6 CVOT, in which no apparent imbalance was observed between oral semaglutide and placebo in the AE reporting of diabetic retinopathy over 16 months (66)
The program includes strategies to address emotional and stress related eating as part of its comprehensive approach
Here's how the ingredients work: Superior formula: four high-quality, complementary ingredients for stimulating hormone GLP-1 and weight loss